This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Urigen Pharmaceuticals, Inc.

Drug Names(s): VLTS-589, DEL-1 (Developmentally Reulated Endothelial Locus-1) + VLTS 934

Description: Deltavasc is a nonviral therapeutic comprising a plasmid-expressing Del-1 formulated with a 5% solution of VLTS 934. VLTS 934 was formulated with the Del-1 gene because it more broadly distributes the gene to cells resulting in increased cellular uptake of the gene and increased production of the angiogenic protein from the cells.

Deal Structure: VLTS-589 was licensed by Valentis from Vanderbilt University.

Deltavasc News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug